James Alan Hayman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
James Alan Hayman has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
Aaron R Sasson
2 shared publications- Daniel Paul Normolle
Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania
2 shared publications - David Herman Ilson
Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York, NY
2 shared publications J C Weeks
2 shared publicationsJ R Harris
2 shared publicationsJames A Posey
2 shared publications
Latest Publications
- 1 September 2015
- Published by Elsevier in Practical Radiation Oncology
- Vol. 5  (5) , 277-281
Learning to Appreciate Swiss Cheese and Other Industrial Engineering Concepts
- 1 September 2015
- Published by Elsevier in Practical Radiation Oncology
- Vol. 5  (5) , 277-281
Learning to Appreciate Swiss Cheese and Other Industrial Engineering Concepts
- 1 March 2014
- Published by Elsevier in Healthcare
- Vol. 2  (1) , 53-62
Delivering high-quality cancer care: The critical role of quality measurement
- 1 March 2014
- Published by Elsevier in Healthcare
- Vol. 2  (1) , 53-62
Delivering high-quality cancer care: The critical role of quality measurement
- Open Access
- 21 August 2013
- Published by Springer Nature in Radiation Oncology
- Vol. 8  (1) , 204
Concurrent whole brain radiotherapy and bortezomib for brain metastasis
Survival of patients with brain metastasis particularly from historically more radio-resistant malignancies remains dismal. A phase I study of concurrent bortezomib and whole brain radiotherapy was conducted to determine the tolerance and safety of this approach in patients with previously untreated brain metastasis.
- 21 August 2013
- Published by Springer Nature in Radiation Oncology
- Vol. 8  (1) , 204
Open AccessConcurrent whole brain radiotherapy and bortezomib for brain metastasis
Survival of patients with brain metastasis particularly from historically more radio-resistant malignancies remains dismal. A phase I study of concurrent bortezomib and whole brain radiotherapy was conducted to determine the tolerance and safety of this approach in patients with previously untreated brain metastasis.
- Open Access
- 3 May 2013
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 105  (11) , 758-759
Informing Patient Decisions Regarding Management of Ductal Carcinoma In Situ
The Institute of Medicine has identified the management of ductal carcinoma in situ (DCIS) as one of the highest priority topics for comparative effectiveness research. With the rise of mammographic screening, the incidence of DCIS has increased dramatically, and currently about a quarter of all newly diagnosed breast cancers are DCIS. Although DCIS is by definition noninvasive, treatment is necessary because of the risk of development into invasive cancer. Therefore, most patients with DCIS face complex management decisions, including whether to undergo breast-conserving surgery or mastectomy, as well as whether to receive adjuvant radiotherapy and/or tamoxifen.
- 3 May 2013
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 105  (11) , 758-759
Open AccessInforming Patient Decisions Regarding Management of Ductal Carcinoma In Situ
The Institute of Medicine has identified the management of ductal carcinoma in situ (DCIS) as one of the highest priority topics for comparative effectiveness research. With the rise of mammographic screening, the incidence of DCIS has increased dramatically, and currently about a quarter of all newly diagnosed breast cancers are DCIS. Although DCIS is by definition noninvasive, treatment is necessary because of the risk of development into invasive cancer. Therefore, most patients with DCIS face complex management decisions, including whether to undergo breast-conserving surgery or mastectomy, as well as whether to receive adjuvant radiotherapy and/or tamoxifen.
- 1 May 2013
- Published by American Society of Clinical Oncology (ASCO) in Journal of Oncology Practice
- Vol. 9  (3) , 158-159
Summary of Oral Abstract Session B: Innovating to Improve Care Quality
These abstracts highlight the multidisciplinary nature of the Quality Care Symposium and share common themes such as their emphasis on real-world data and discourse with an aim for quality improvement.
- 1 May 2013
- Published by American Society of Clinical Oncology (ASCO) in Journal of Oncology Practice
- Vol. 9  (3) , 158-159
Summary of Oral Abstract Session B: Innovating to Improve Care Quality
These abstracts highlight the multidisciplinary nature of the Quality Care Symposium and share common themes such as their emphasis on real-world data and discourse with an aim for quality improvement.
- 31 July 2012
- Published by Springer Nature in Investigational New Drugs
- Vol. 31  (2) , 435-442
Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer
Summary Introduction This phase II trial investigated chemoradiation followed by surgery and 2 years of adjuvant tetrathiomolybdate (TM) for resectable esophageal cancer. Methods Patients with resectable, locally advanced esophageal cancer received neoadjuvant cisplatin 60 mg/m2 (days 1 and 22), paclitaxel 60 mg/m2 (days 1, 8, 15, and 22), and 45 Gy hyperfractionated radiotherapy for 3 weeks followed by transhiatal esophagectomy. TM 20 mg PO QD was started 4 weeks post-op, and continued for 2 years to maintain the ceruloplasmin level between 5 and 15 mg/dl. Results Sixty-nine patients were enrolled (median age, 60 years). Sixty-six patients underwent surgery and 61 patients had a complete resection. Histologic complete response rate was 10 %. Twenty-one patients did not receive TM (metastases noted in the peri-operative period, prolonged post-operative recovery time, or patient refusal). Forty-eight patients started TM; 14 completed 24 months of treatment, 11 completed 10–18 months, 15 completed 2–8 months, and 8 completed ≤1 month. Twenty-seven patients had disease recurrence. With a median follow-up of 55 months, 25 patients were alive without disease, 1 was alive with disease, and 43 have died. Three-year recurrence-free survival was 44 % (95 % CI, 32–55 %) and the three-year overall survival was 45 % (95 % CI 33–56 %). Conclusions TM is an antiangiogenic agent that is well tolerated in the adjuvant setting. Disease-free survival and overall survival are promising when compared to historical controls treated at our institution with a similar regimen that did not include TM. However, the challenges associated with prolonged administration limit further investigation.
- 31 July 2012
- Published by Springer Nature in Investigational New Drugs
- Vol. 31  (2) , 435-442
Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer
Summary Introduction This phase II trial investigated chemoradiation followed by surgery and 2 years of adjuvant tetrathiomolybdate (TM) for resectable esophageal cancer. Methods Patients with resectable, locally advanced esophageal cancer received neoadjuvant cisplatin 60 mg/m2 (days 1 and 22), paclitaxel 60 mg/m2 (days 1, 8, 15, and 22), and 45 Gy hyperfractionated radiotherapy for 3 weeks followed by transhiatal esophagectomy. TM 20 mg PO QD was started 4 weeks post-op, and continued for 2 years to maintain the ceruloplasmin level between 5 and 15 mg/dl. Results Sixty-nine patients were enrolled (median age, 60 years). Sixty-six patients underwent surgery and 61 patients had a complete resection. Histologic complete response rate was 10 %. Twenty-one patients did not receive TM (metastases noted in the peri-operative period, prolonged post-operative recovery time, or patient refusal). Forty-eight patients started TM; 14 completed 24 months of treatment, 11 completed 10–18 months, 15 completed 2–8 months, and 8 completed ≤1 month. Twenty-seven patients had disease recurrence. With a median follow-up of 55 months, 25 patients were alive without disease, 1 was alive with disease, and 43 have died. Three-year recurrence-free survival was 44 % (95 % CI, 32–55 %) and the three-year overall survival was 45 % (95 % CI 33–56 %). Conclusions TM is an antiangiogenic agent that is well tolerated in the adjuvant setting. Disease-free survival and overall survival are promising when compared to historical controls treated at our institution with a similar regimen that did not include TM. However, the challenges associated with prolonged administration limit further investigation.
- 1 March 2011
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 79  (3) , 847-852
Distribution of Proliferating Bone Marrow in Adult Cancer Patients Determined Using FLT-PET Imaging
- 1 March 2011
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 79  (3) , 847-852
Distribution of Proliferating Bone Marrow in Adult Cancer Patients Determined Using FLT-PET Imaging
- 1 January 2011
- Published by Elsevier in Practical Radiation Oncology
- Vol. 1  (1) , 15
Improving safety in radiation oncology
- 1 January 2011
- Published by Elsevier in Practical Radiation Oncology
- Vol. 1  (1) , 15
Improving safety in radiation oncology
- 14 August 2009
- Published by Springer Nature
- p. 351-381
Site-Directed Therapy for Lung Cancer Metastases
- 14 August 2009
- Published by Springer Nature
- p. 351-381
Site-Directed Therapy for Lung Cancer Metastases
- 1 May 2009
- Published by American Society of Clinical Oncology (ASCO) in Journal of Oncology Practice
- Vol. 5  (3) , 108-109
Treatment Summaries in Radiation Oncology and Their Role in Improving Patients' Quality of Care: Past, Present, and Future
Through treatment summaries, radiation oncologists can build upon past efforts and improve the future quality of care for all patients receiving treatment with radiation. This article looks at what treatment summaries should contain and how they might be improved.
- 1 May 2009
- Published by American Society of Clinical Oncology (ASCO) in Journal of Oncology Practice
- Vol. 5  (3) , 108-109
Treatment Summaries in Radiation Oncology and Their Role in Improving Patients' Quality of Care: Past, Present, and Future
Through treatment summaries, radiation oncologists can build upon past efforts and improve the future quality of care for all patients receiving treatment with radiation. This article looks at what treatment summaries should contain and how they might be improved.